Mablink Bioscience News Today

Lazard and Elaia Partners plan to launch a late-stage and growth equity fund focused on Europe and managed by a new jointly owned asset management firm based in Paris ...

The ImmunoGen deal, which is expected to close in the middle of 2024, is also estimated to be accretive to AbbVie’s diluted earnings per share beginning in 2027.

The discovery collab between Lilly and Prism, worth north of $600 million, promises to yield fresh targets that are readily druggable with small molecules.

Notably, the Lilly deal is also expected to extend Beam’s cash runway to the second half of 2026.

The stock market gave up gains Thursday morning, as small caps and the IBD 50 also lagged amid a day full of events to watch.

BioPharma

By Ben Glickman Eli Lilly agreed to acquire preclinical biotechnology company Mablink Bioscience. Lyon, France-based Mablink, which develops antibody-drug...

Health-care companies declined as traders stepped back from makers of Covid 19 products. Pfizer tumbled to the lowest level since mid2020 as investors braced...

Health-care companies declined as traders stepped back from makers of Covid 19 products. Pfizer tumbled to the lowest level since mid2020 as investors braced for a pronounced slowdown in sales... -October 18, 2023 at 05:22 pm EDT - MarketScreener

By Ben Glickman Eli Lilly agreed to acquire preclinical biotechnology company Mablink Bioscience. Lyon, France-based Mablink, which develops antibody-drug conjugates, a new class of cancer...